Personalised Medicine-Implementation to the Healthcare System in Europe (Focus Group Discussions)

被引:37
作者
Stefanicka-Wojtas, Dorota [1 ]
Kurpas, Donata [2 ]
机构
[1] Wroclaw Med Univ, Clin Trials Dept, PL-50556 Wroclaw, Poland
[2] Wroclaw Med Univ, Family Med Dept, PL-51141 Wroclaw, Poland
基金
欧盟地平线“2020”;
关键词
personalized medicine; interregional cooperation; barriers; facilitators; healthcare systems; BARRIERS;
D O I
10.3390/jpm13030380
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Personalized medicine (PM) is an approach based on understanding the differences between patients with the same disease and represents a change from the "one size fits all" concept. According to this concept, appropriate therapies should be selected for specific groups of patients. PM makes it possible to predict whether a particular therapy will be effective for a particular patient. PM will still have to overcome many challenges and barriers before it can be successfully implemented in healthcare systems. However, it is essential to remember that PM is not a medical revolution but an evolution. Methods: Three focus groups were conducted, to achieve the purpose of this study, which was to identify the barriers and facilitators existing to the implementation of PM and to highlight existing practices in European countries. Focus group discussions covered the areas of barriers and facilitators to the implementation of personalized medicine. Results: This section describes the results of the focus groups that covered the areas of barriers and facilitators of personalized medicine implementation. Conclusions: Personalized medicine faces many challenges and barriers before it can be successfully implemented in health systems. The translation of PM to European countries, differences in regulations, high costs of new technologies, and reimbursement are the reasons for the delay in PM implementation.
引用
收藏
页数:10
相关论文
共 19 条
[1]  
[Anonymous], 2015, OFFICIAL J EUROPEAN
[2]   An overview of Personalized Medicine landscape and policies in the European Union [J].
Beccia, F. ;
Hoxhaj, I ;
Castagna, C. ;
Strohaeker, T. ;
Cadeddu, C. ;
Ricciardi, Walter ;
Boccia, S. .
EUROPEAN JOURNAL OF PUBLIC HEALTH, 2022, 32 (06) :844-851
[3]   Precision medicine/personalized medicine: a critical analysis of movements in the transformation of biomedicine in the early 21st century [J].
Bernstein Iriart, Jorge Alberto .
CADERNOS DE SAUDE PUBLICA, 2019, 35 (03)
[4]  
brookings, REP ADV PREC MED AG
[5]   Personalized medicine and education: the challenge [J].
Haiech, Jacques ;
Kilhoffer, Marie-Claude .
CROATIAN MEDICAL JOURNAL, 2012, 53 (04) :298-300
[6]   An Index of Barriers for the Implementation of Personalised Medicine and Pharmacogenomics in Europe [J].
Horgan, Denis ;
Jansen, Marleen ;
Leyens, Lada ;
Lal, Jonathan A. ;
Sudbrak, Ralf ;
Hackenitz, Erica ;
Busshoff, Ulrike ;
Ballensiefen, Wolfgang ;
Brand, Angela .
PUBLIC HEALTH GENOMICS, 2014, 17 (5-6) :287-298
[7]   Challenges and Solutions for Integrating and Financing Personalized Medicine in Healthcare Systems: A Systematic Literature Review [J].
Kalouguina, Veronika ;
Wagner, Joel .
JOURNAL OF RISK AND FINANCIAL MANAGEMENT, 2020, 13 (11)
[8]  
Lawler M, 2017, NEW BIOETH, V23, P64, DOI 10.1080/20502877.2017.1314883
[9]   Personalized Nursing Care in Precision-Medicine Era [J].
Lopes-Junior, Luis Carlos .
SAGE OPEN NURSING, 2021, 7
[10]   The Future of Precision Medicine: Potential Impacts for Health Technology Assessment [J].
Love-Koh, James ;
Peel, Alison ;
Rejon-Parrilla, Juan Carlos ;
Ennis, Kate ;
Lovett, Rosemary ;
Manca, Andrea ;
Chalkidou, Anastasia ;
Wood, Hannah ;
Taylor, Matthew .
PHARMACOECONOMICS, 2018, 36 (12) :1439-1451